Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
A better understanding of natural variation in neutralization resistance and fitness of diverse hepatitis C virus (HCV) envelope (E1E2) variants will be critical to guide rational development of an HCV vaccine. This work has been hindered by inadequate genetic diversity in viral panels and by a lack of standardization of HCV entry assays. Neutralization assays generally use lentiviral pseudoparticles expressing HCV envelope proteins (HCVpp) or chimeric full-length viruses that are replication competent in cell culture (HCVcc). There have been few systematic comparisons of specific infectivities of E1E2-matched HCVcc and HCVpp, and to our knowledge, neutralization of E1E2-matched HCVpp and HCVcc has never been compared using a diverse panel of human broadly neutralizing monoclonal antibodies (bNAbs) targeting distinct epitopes. Here, we describe an efficient method for introduction of naturally occurring E1E2 genes into a full-length HCV genome, producing replication-competent chimeric HCVcc. We generated diverse panels of E1E2-matched HCVcc and HCVpp and measured the entry-mediating fitness of E1E2 variants using the two systems. We also compared neutralization of E1E2-matched HCVcc and HCVpp by a diverse panel of human bNAbs targeting epitopes across E1E2. We found no correlation between specific infectivities of E1E2-matched HCVcc versus HCVpp, but found a very strong positive correlation between relative neutralization resistance of these same E1E2-matched HCVcc and HCVpp variants. These results suggest that quantitative comparisons of neutralization resistance of E1E2 variants can be made with confidence using either HCVcc or HCVpp, allowing the use of either or both systems to maximize diversity of neutralization panels.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Lisa N
LN
Wasilewski
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.|Department of Oncology, Johns Hopkins University, Baltimore, MD 21205, USA.
Stuart C
SC
Ray
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.
Justin R
JR
Bailey
D057134:Antibodies, Neutralizing / Q000276:immunology / Q000494:pharmacology*; D016174:Hepacivirus / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D006526:Hepatitis C / Q000821:virology; D018937:Hepatitis C Antibodies / Q000276:immunology / Q000494:pharmacology*; D006801:Humans; D009500:Neutralization Tests; D014759:Viral Envelope Proteins / Q000276:immunology; D014779:Virus Replication / Q000187:drug effects*
D057134:Antibodies, Neutralizing; D018937:Hepatitis C Antibodies; D014759:Viral Envelope Proteins
J Virol. 2008 Jun;82(12):6067-72
18385242
N Engl J Med. 2013 May 16;368(20):1859-61
23675657
J Clin Invest. 2015 Jan;125(1):437-47
25500884
PLoS Pathog. 2012;8(4):e1002653
22511875
J Virol. 2008 Oct;82(19):9647-56
18667498
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
17392433
J Virol. 2000 Nov;74(22):10407-16
11044085
J Virol. 2015 Aug;89(15):7758-75
25995244
Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):997-1002
18195353
J Virol. 2014 Sep;88(18):10584-97
24990994
J Virol. 2013 Jan;87(1):37-51
23097455
Gastroenterology. 2009 Jun;136(7):2377-86
19303013
J Virol. 2010 Oct;84(19):10159-68
20668082
J Viral Hepat. 2009 Sep;16(9):621-32
19302336
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6
12761383
J Virol. 2011 Jan;85(1):596-605
20962076
J Biol Chem. 2014 Jul 4;289(27):18904-13
24838241
Hepatology. 2000 Sep;32(3):618-25
10960458
Mol Biol Evol. 1993 May;10(3):512-26
8336541
J Gen Virol. 2016 Sep;97(9):2187-93
27329374
J Gen Virol. 2016 Sep;97(9):2265-79
27384448
J Virol. 2013 Jun;87(11):6521-5
23536672
Gastroenterology. 2010 Oct;139(4):1355-64
20600021
Gastroenterology. 2012 Jul;143(1):223-233.e9
22503792
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4560-5
15767578
Mol Biol Evol. 2013 Dec;30(12):2725-9
24132122
Clin Infect Dis. 2012 Jul;55 Suppl 1:S10-5
22715208
J Virol. 2004 Feb;78(3):1448-55
14722300
J Virol. 2009 Dec;83(24):12680-91
19793818
J Virol. 2010 Nov;84(22):12048-57
20826689
Gastroenterology. 2016 Jan;150(1):206-217.e4
26404951
PLoS Pathog. 2012;8(8):e1002895
22952447
J Virol. 2007 Aug;81(15):8072-9
17507469
Hepatology. 2005 Dec;42(6):1429-36
16317673
J Virol. 2016 Jan 27;90(7):3773-82
26819308
Hepatology. 2014 Jun;59(6):2140-51
24425349
J Virol. 2013 Feb;87(3):1385-99
23152512
Hepatology. 2008 Jan;47(1):17-24
17941058
Hepatology. 2014 Nov;60(5):1551-62
25043937
J Infect Dis. 2015 Sep 15;212(6):914-23
25754978
J Virol. 2009 Jun;83(12):6149-60
19321602
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3805-9
16484368
J Virol. 2015 Dec 23;90(7):3288-301
26699643
Nat Med. 2008 Jan;14(1):25-7
18064037
JAMA. 2000 Jul 26;284(4):450-6
10904508
Gastroenterology. 2007 Nov;133(5):1614-26
17983807
Virology. 2014 Jun;458-459:190-208
24928051
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10149-54
15220475
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7270-4
15123813
Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9505-10
23690609
J Virol. 2011 Mar;85(6):2891-906
21177811
Hepatology. 2009 Feb;49(2):364-77
19148942
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10
22492964
J Biol Chem. 2003 Oct 24;278(43):41624-30
12913001
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14416-21
12391335
J Virol. 2012 Jul;86(13):7256-67
22532692
J Virol. 2004 Aug;78(16):8496-505
15280458
J Virol. 2016 Apr 14;90(9):4530-43
26912610
Ann Intern Med. 2006 May 16;144(10):705-14
16702586